1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 10 (Search time: 0.003 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Doxorubicin overcomes resistance to drozitumab by antagonizing inhibitor of apoptosis proteins (IAPS)Zinonos, I.; Labrinidis, A.; Liapis, V.; Hay, S.; Panagopoulos, V.; Denichilo, M.; Ponomarev, V.; Ingman, W.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2014Pharmacologic inhibition of bone resorption prevents cancer-induced osteolysis but enhances soft tissue metastasis in a mouse model of osteolytic breast cancerZinonos, I.; Luo, K.; Labrinidis, A.; Liapis, V.; Hay, S.; Panagopoulos, V.; Denichilo, M.; Ko, C.; Yue, G.; Lau, C.; Ingman, W.; Ponomarev, V.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2015Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcomaLiapis, V.; Labrinidis, A.; Zinonos, I.; Hay, S.; Ponomarev, V.; Panagopoulos, V.; DeNichilo, M.; Ingman, W.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2011Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivoZinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2016Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine modelsLiapis, V.; Zinonos, I.; Labrinidis, A.; Hay, S.; Ponomarev, V.; Panagopoulos, V.; Zysk, A.; DeNichilo, M.; Ingman, W.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2009Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancerZinonos, I.; Labrinidis, A.; Lee, M.; Liapis, V.; Hay, S.; Ponomarev, V.; Diamond, P.; Zannettino, A.; Findlay, D.; Evdokiou, A.
2009Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myelomaLabrinidis, A.; Diamond, P.; Martin, S.; Hay, S.; Liapis, V.; Zinonos, I.; Sims, N.; Atkins, G.; Vincent, C.; Ponomarev, V.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2009Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse modelLabrinidis, A.; Hay, S.; Liapis, V.; Ponomarev, V.; Findlay, D.; Evdokiou, A.
2017Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancerZysk, A.; DeNichilo, M.; Panagopoulos, V.; Zinonos, I.; Liapis, V.; Hay, S.; Ingman, W.; Ponomarev, V.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.
2017Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcomaLiapis, V.; Zysk, A.; DeNichilo, M.; Zinonos, I.; Hay, S.; Panagopoulos, V.; Shoubridge, A.; Difelice, C.; Ponomarev, V.; Ingman, W.; Atkins, G.; Findlay, D.; Zannettino, A.; Evdokiou, A.

Discover